✨ Inflammatory #Myositis✨ 👉 Excellent summary of Autoantibodies, Immune alterations and Distinct Phenotypes by Dr. Lisa Rider #EULAR2022 https://t.co/KLzmLUGk9Z

Watch: New 2022 EULAR RA Treatment Guidelines https://t.co/mF4cKJLtbr #EULAR2022 https://t.co/oI8p6gL0Tf

• https://bit.ly/3MeKRpM

Teng et al BLISS-BELIEVE Biomarker outcome RCT Sequential belimumab-rituximab in SLE. Certainly appears to be a serologic benefit on dsDNA, C3/4. But we need clinical parameters to correlate with this. @RheumNow #EULAR2022 OP0281 https://t.co/iEeSN0SNcr https://t.co/HN8ya4QZLU

• EULAR Abstract Archive

Manzi et al. Data on anifrolumab from TULIP studies on depression/suicidality. No effect. @RheumNow #EULAR2022 OP0282 https://t.co/5n7HBqzLkX https://t.co/fq4dxskJaA

• EULAR Abstract Archive

Roberto Giacomeilli from Italy explaining the mechanisms on how COVID-19 may cause rheumatic disease #EULAR2022 @RheumNow https://t.co/a2kTT7vcRx

Nossent et al Hospitalisation with opportunistic infection twice as high in RA vs AxSpA/PsA. Has IMPROVED over biologic era. To me, suggests benefits of proper disease control on infection risk @RheumNow #EULAR2022 OP0274 https://t.co/cqUoRti4We https://t.co/Ozz7jH3z4N

• EULAR Abstract Archive

Catching up with Jack, a great teacher and educator @RheumNow #rheum #rheumedu #EULAR2022 https://t.co/2wqbhpIb2P

LDA/MDA achieved in 60% of PsA pts on (mostly) bDMARDs. Combo baseline features: TJC>3, SJC>5, CRP>10 mg/l, HAQ>0.5, enthesitis, dactylitis, BMI>30  & sDMARDs tx constitutes negative predictive impact on MDA/LDA after 1 yr. #EULAR2022 POS0080 @RheumNow https://t.co/PugwiuSMPm https://t.co/nqadEjA3Xe

• POS0080 PROGNOSTIC FACTORS ASSOCIATED WITH NON-REMISSION OR LOW DISEASE ACTIVIT…

Izokibep - potent and small molecule IL-17A inhibitor Phase 2 study in PsA patients Fast onset, met ACR50 primary endpoint AE included site reaction and candida infection @RheumNow #EULAR2022 ABST#OP0258 https://t.co/vZ4xmnhyhl

I could listen to Dennis McGonagle talk about enthesitis all day. If you missed it, one to check out later #EULAR2022 @RheumNow https://t.co/8pRKqMB06j

Add on MTX does not impair UST immunogenicity in PsA. #EULAR2022 POS0079 @RheumNow https://t.co/CalEn7KpsX https://t.co/NZUqdX0XKo

• POS0079 DOES METHOTREXATE IMPACT USTEKINUMAB IMMUNOGENICITY IN PATIENTS WITH AC…

52 wk trial using MSK Ultrasound study on PsA receiving secukinumab showed an early and continued improvement in GLOESS scores. Synovial hypertrophy most responsive. Hands and feet, wrist and knees most affected and responsive. @RheumNow #EULAR2022 ABST#OP0260 https://t.co/jeQezIWLxa

#POS0757 #EULAR2022 What is the perception of #lupus patients on #COVID19 recovery? A survey of 202 pts from BILAG-BR (N=20 case+, 3 hospitalised) reported full recovery from covid in only 1/3 of patients. These pts would need extra support @RheumNow https://t.co/SdH223Lfoa

Novel composite DAPSA LDA +IGA < or = to 1 may be a reliable predictor in long-term PsA skin/joint response (and easier to get than PASDAS in clinic.) @AlexisOgdie #EULAR2022 POS0082 @RheumNow https://t.co/dmMjGcsIcm https://t.co/BHRlGenCyl

• POS0082 A NOVEL PSORIATIC ARTHRITIS COMPOSITE ENDPOINT COMBINING TREATMENT TARG…

Style guide: welcome to the modern era of #EULAR2022 (and here I am, stuck-in-the-mud still wearing my collared shirt/blue blazer) @RheumNow https://t.co/MXXHWF7Q47